FDA Approval Insights: Rucaparib for BRCA Mutation–Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MD
Share
Subscribe
David Morris, MD, FACS, and Alan H. Bryce, MD, discuss the FDA’s full approval of rucaparib for BRCA mutation–associated mCRPC.
Welcome to OncLive On Air®! I’m your host today, Kyle Doherty.
OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, we spoke with David Morris, MD, FACS, and Alan H. Bryce, MD. Dr Morris is the president of Urology Associates, PC, in Nashville, Tennessee. Dr Bryce is a medical oncologist and the chief clinical officer of City of Hope Cancer Center Phoenix in Arizona.
In our exclusive interview, Drs Morris and Bryce discussed the clinical implications of the FDA’s full approval of rucaparib (Rubraca) for BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC), including the notable data that supported the regulatory decision and how this agent fits into the mCRPC treatment paradigm.